There has been an important update for the Duchenne muscular dystrophy (DMD) community about two treatments, AMONDYS 45 and VYONDYS 53. These medicines are exon-skipping therapies approved under the FDA’s accelerated approval pathway in the USA for patients with DMD who have mutations amenable to exon 45 and exon 53 skipping, respectively.
The company, Sarepta, behind these therapies has completed a large study called ESSENCE and has shared the results with the U.S. Food and Drug Administration (FDA). The ESSENCE study is a global, Phase 3 randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AMONDYS 45 and VYONDYS 53 compared to placebo in participants aged 6-13 years old, with Duchenne amenable to exon 45 or 53 skipping.
Sarepta is now planning to apply for full, traditional approval of both treatments in the United States. This step is important because it means there is growing evidence from both clinical trials and from real-world use that these therapies may be making a meaningful difference.
For Canadian families, this kind of progress in the U.S. can be an encouraging sign, but it does not automatically mean access in Canada. Health Canada has its own review process, and decisions about whether a treatment is approved and funded can take additional time. However, strong evidence from large studies and real-world experience can help support future submissions and discussions here in Canada, which is why updates like this matter.
While progress can sometimes feel slow, each step forward builds on the strength and involvement of the Duchenne community. The participation of patients and families in research, care, and advocacy continues to play a vital role in moving new treatments closer to reality. These advances represent not just scientific progress, but growing hope for longer, stronger, and more active lives for Canadians living with Duchenne.comes. The DMD community will be watching closely as this growing body of evidence helps shape future care and treatment decisions.
Read the official Press Release and the Letter to the Community below to learn more.
Want to know more about Duchenne Research?
Scientists and medical experts have been tirelessly pursuing diverse approaches to defeat Duchenne muscular dystrophy. From tackling the root cause to alleviating symptoms, the field of research is vast and promising. Explore the various strategies being developed and tested, and gain insights into the future of muscular dystrophy treatment: